Breaking News Instant updates and real-time market news.

XLRN

Acceleron

$42.11

-0.83 (-1.93%)

09:05
01/08/18
01/08
09:05
01/08/18
09:05

Acceleron announces 'positive' preliminary results from Part 1 of ACE-083 trial

Acceleron Pharma announced positive preliminary results for the first two cohorts in Part 1 of the Phase 2 clinical trial with ACE-083 in patients with facioscapulohumeral dystrophy, a rare genetic muscle disorder that results in progressive focal muscle loss and weakness. The company plans to initiate Part 2 of the ACE-083 FSHD Phase 2 trial during 2Q18. Part 1 of the Phase 2 trial is an open-label, dose-escalation study of ACE-083 designed to evaluate safety as well as changes in total muscle volume in up to 36 patients with FSHD. Preliminary results include data from 23 patients evaluable for magnetic resonance imaging among two different cohorts. Each patient received ACE-083 as a unilateral intramuscular injection once every three weeks for 12 weeks. Total muscle volume changes were measured by MRI relative to baseline at 3 weeks after the last injection of ACE-083. Based on overlap in dosing on a milligram per gram muscle analysis, dose cohorts were pooled for the analyses of each muscle. The tibialis anterior, which is located in the lower leg, is the main muscle responsible for ankle dorsiflexion, or the ability to lift the front of the foot when taking a step. Over 70% of FSHD patients experience tibialis anterior weakness over the course of their disease, which can lead to general decreased mobility and an increased frequency of falling. The TA cohorts generated a mean total muscle volume increase of 12.6%. The TA cohorts produced a mean decrease or improvement in muscle fat fraction of 5.3%. The biceps brachii, which is located in the upper arm, is a major muscle responsible for elbow flexion, or the ability to lift the lower arm. A majority of FSHD patients experience biceps brachii weakness early in their disease, which leads to the inability to lift objects or perform other important daily activities without assistance. The BB cohorts generated a mean total muscle volume increase of 13.2%. The BB cohorts produced a mean decrease or improvement in muscle fat fraction of 0.6%. In the BB cohorts, the majority of patients had less intramuscular fat at baseline relative to the patients in the TA cohorts. Patients with higher fat fraction in the BB cohorts at baseline demonstrated larger decreases in fat fraction with treatment. Strength and function tests are being explored in Part 1 to assist with the design of the randomized, double-blind, placebo-controlled Part 2 of the study. Given the lack of placebo control and small sample size of patients in Part 1, no conclusions can be made on the strength and function assessments at this time. Effects of ACE-083 on strength and function versus a placebo-control will be evaluated in Part 2 of the study. There were no serious adverse events reported. The most common adverse events were injection site related and grades 1-2. One patient experienced a related grade 3 non-serious adverse event of lower leg intramuscular swelling. This patient fully recovered and was discontinued from the study.

  • 08

    Jan

XLRN Acceleron
$42.11

-0.83 (-1.93%)

09/20/17
JEFF
09/20/17
NO CHANGE
Target $160
JEFF
Buy
Jefferies sees Celgene shares 'grinding' higher into 2018
Commentary from partner Acceleron Pharma's (XLRN) R&D day indicates Celgene (CELG) will announce lots of data in 2018, Jefferies analyst Michael Yee tells investors in a research note. He sees Celgene shares "grinding higher" over the next few months and into 2018 ahead of three major Phase III datasets: GED-301 in Crohn's, Ozanimod in ulcerative colitis and partner Acceleron's luspatercept in beta-thalassemia. The analyst keeps a Buy rating on Celgene with a $160 price target.
10/12/17
HCWC
10/12/17
INITIATION
Target $57
HCWC
Buy
Acceleron initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Edward White started Acceleron Pharma with a Buy rating and $57 price target. The analyst thinks luspatercept could be brought to the market by late 2019, and will achieve blockbuster sales by 2026.
11/07/17
HCWC
11/07/17
NO CHANGE
Target $62
HCWC
Buy
Acceleron price target raised to $62 from $57 at H.C. Wainwright
H.C. Wainwright analyst Edward White raised his price target for Acceleron Pharma to $62 following the company's Q3 results and pipeline update citing an increase in cash levels. Acceleron indicated that it will have enough cash after its September offering to fund operations into 2021, White points out. He keeps an Outperform rating on the shares.
11/14/17
FBCO
11/14/17
NO CHANGE
Target $51
FBCO
Outperform
Acceleron price target raised to $51 from $35 at Credit Suisse
Credit Suisse analyst Alethia Young raised her price target for Acceleron to $51 from $35 due to increased confidence in the commercial market opportunity for Phase 3 asset luspatercept. The analyst reiterates an Outperform rating on the shares.

TODAY'S FREE FLY STORIES

QD

Qudian

$12.50

0.1 (0.81%)

12:45
01/22/18
01/22
12:45
01/22/18
12:45
Options
Qudian Inc call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INTC

Intel

$44.82

0.34 (0.76%)

12:44
01/22/18
01/22
12:44
01/22/18
12:44
Hot Stocks
Breaking Hot Stocks news story on Intel »

Intel says made good…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 25

    Jan

INTC

Intel

$44.82

0.34 (0.76%)

12:43
01/22/18
01/22
12:43
01/22/18
12:43
Hot Stocks
Breaking Hot Stocks news story on Intel »

Intel recommends stopping…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 25

    Jan

BAC

Bank of America

$31.76

0.04 (0.13%)

12:43
01/22/18
01/22
12:43
01/22/18
12:43
Periodicals
Bank of America eliminates remaining free-checking eBanking accounts, WSJ says »

Bank of America has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Feb

MS

Morgan Stanley

$57.02

-0.44 (-0.77%)

12:38
01/22/18
01/22
12:38
01/22/18
12:38
Hot Stocks
Breaking Hot Stocks news story on Morgan Stanley »

Morgan Stanley says…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CAR

Avis Budget

$45.78

2.43 (5.61%)

12:35
01/22/18
01/22
12:35
01/22/18
12:35
Options
Avis Budget put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AKTX

Akari Therapeutics

$3.59

-0.01 (-0.28%)

12:30
01/22/18
01/22
12:30
01/22/18
12:30
Conference/Events
Akari Therapeutics management to meet with William Blair »

Group luncheon to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

12:25
01/22/18
01/22
12:25
01/22/18
12:25
Conference/Events
UBS REITs analyst holds an analyst/industry conference call »

REITs Analyst Yulico…

OMER

Omeros

$16.70

-0.02 (-0.12%)

12:24
01/22/18
01/22
12:24
01/22/18
12:24
Hot Stocks
Omeros off highs following cautious Twitter mention »

Shares of Omeros are…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPY

SPDR S&P 500 ETF Trust

$281.54

1.125 (0.40%)

, SPX

S&P 500

12:21
01/22/18
01/22
12:21
01/22/18
12:21
General news
Breaking General news story on SPDR S&P 500 ETF Trust, S&P 500 »

Schumer says deal reached…

SPY

SPDR S&P 500 ETF Trust

$281.54

1.125 (0.40%)

SPX

S&P 500

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMD

AMD

$12.59

0.12 (0.96%)

12:20
01/22/18
01/22
12:20
01/22/18
12:20
Options
AMD attracts a bullish three-way spread before shares tick higher »

AMD attracts a bullish…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jan

BG

Bunge

$80.40

2.84 (3.66%)

, ADM

Archer Daniels

$42.21

1.2505 (3.05%)

12:19
01/22/18
01/22
12:19
01/22/18
12:19
Recommendations
Bunge, Archer Daniels, Glencore analyst commentary  »

Credit Suisse says Archer…

BG

Bunge

$80.40

2.84 (3.66%)

ADM

Archer Daniels

$42.21

1.2505 (3.05%)

GLNCY

Glencore

$11.29

-0.02 (-0.18%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Feb

  • 14

    Feb

$NSD

NASDAQ Market Internals

12:17
01/22/18
01/22
12:17
01/22/18
12:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

12:16
01/22/18
01/22
12:16
01/22/18
12:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

K

Kellogg

$66.78

0.16 (0.24%)

12:15
01/22/18
01/22
12:15
01/22/18
12:15
Options
Kellogg put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Feb

12:10
01/22/18
01/22
12:10
01/22/18
12:10
General news
FX Action: USD-JPY »

FX Action: USD-JPY has…

BIVV

Bioverativ

$64.11

1.36 (2.17%)

, JUNO

Juno Therapeutics

$67.81

-3.56 (-4.99%)

12:08
01/22/18
01/22
12:08
01/22/18
12:08
General news
On The Fly: Top stock stories at midday »

Stocks opened mixed, with…

BIVV

Bioverativ

$64.11

1.36 (2.17%)

JUNO

Juno Therapeutics

$67.81

-3.56 (-4.99%)

VR

Validus

$67.50

20.775 (44.47%)

SNY

Sanofi

$43.23

-1.37 (-3.07%)

CELG

Celgene

$102.65

0.93 (0.91%)

AIG

AIG

$61.03

-0.525 (-0.85%)

IDRA

Idera Pharmaceuticals

$2.55

0.145 (6.03%)

BCRX

BioCryst

$5.59

-0.09 (-1.58%)

SANM

Sanmina

$35.45

0.5 (1.43%)

ARRY

Array BioPharma

$13.14

0.26 (2.02%)

FE

FirstEnergy

$33.23

3.83 (13.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 22

    Jan

  • 22

    Jan

  • 22

    Jan

  • 22

    Jan

  • 22

    Jan

  • 25

    Jan

  • 25

    Jan

  • 29

    Jan

  • 02

    Feb

  • 09

    Feb

  • 14

    Feb

  • 16

    Feb

  • 20

    Feb

  • 21

    Feb

  • 08

    Mar

  • 25

    Mar

  • 25

    Apr

  • 02

    May

  • 30

    Jun

  • 30

    Jun

SPX

S&P 500

, SPY

SPDR S&P 500 ETF Trust

$281.18

0.765 (0.27%)

12:00
01/22/18
01/22
12:00
01/22/18
12:00
Periodicals
Senators have enough votes to end government shutdown, NBC reports 

Reference Link

SPX

S&P 500

SPY

SPDR S&P 500 ETF Trust

$281.18

0.765 (0.27%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BIVV

Bioverativ

$64.11

1.36 (2.17%)

, SNY

Sanofi

$43.22

-1.385 (-3.11%)

12:00
01/22/18
01/22
12:00
01/22/18
12:00
Hot Stocks
Hemophilia makers jump after Sanofi acquires peer Bioverativ for huge premium »

Shares of drug companies…

BIVV

Bioverativ

$64.11

1.36 (2.17%)

SNY

Sanofi

$43.22

-1.385 (-3.11%)

PFE

Pfizer

$36.88

-0.06 (-0.16%)

JNJ

Johnson & Johnson

$147.21

-0.15 (-0.10%)

ALNY

Alnylam

$124.83

0.84 (0.68%)

CBIO

Catalyst Biosciences

$19.49

0.86 (4.62%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 23

    Jan

  • 25

    Jan

  • 30

    Jan

  • 06

    Feb

  • 08

    Feb

  • 14

    Feb

  • 16

    Feb

  • 08

    Mar

  • 08

    Mar

  • 25

    Mar

  • 25

    Apr

  • 02

    May

IRIX

IRIDEX

$7.46

-0.11 (-1.45%)

12:00
01/22/18
01/22
12:00
01/22/18
12:00
Hot Stocks
BlueLine Partners reports 8.5% passive stake in IRIDEX »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OLN

Olin

$37.04

0.155 (0.42%)

12:00
01/22/18
01/22
12:00
01/22/18
12:00
Options
Opening activity in Olin calls »

Opening activity in Olin…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Feb

BK

BNY Mellon

$57.21

0.6 (1.06%)

11:58
01/22/18
01/22
11:58
01/22/18
11:58
Hot Stocks
BNY Mellon to launch FX prime brokerage service »

BNY Mellon announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Mar

JUNO

Juno Therapeutics

$67.81

-3.56 (-4.99%)

, CELG

Celgene

$102.65

0.93 (0.91%)

11:54
01/22/18
01/22
11:54
01/22/18
11:54
Downgrade
Juno Therapeutics, Celgene rating change  »

Juno Therapeutics…

JUNO

Juno Therapeutics

$67.81

-3.56 (-4.99%)

CELG

Celgene

$102.65

0.93 (0.91%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 25

    Jan

  • 25

    Jan

  • 16

    Feb

  • 25

    Mar

PM

Philip Morris

$109.21

0.29 (0.27%)

, XXII

22nd Century

$3.94

0.08 (2.07%)

11:52
01/22/18
01/22
11:52
01/22/18
11:52
Periodicals
FDA advisers to vote on clearance for Philip Morris iQOS device, Reuters says »

U.S. health advisers are…

PM

Philip Morris

$109.21

0.29 (0.27%)

XXII

22nd Century

$3.94

0.08 (2.07%)

BTI

British American Tobacco

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WPZ

Williams Partners

$43.16

0.61 (1.43%)

11:50
01/22/18
01/22
11:50
01/22/18
11:50
Options
Williams Partners with notable call buying »

Williams Partners with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.